STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners (NCT06613204)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD). STELLA-FTD is a multicomponent videoconference-based intervention designed to facilitate effective use of community and peer resources to foster effective management of behavioral and psychological symptoms of dementia. The study is recruiting families from across the United States.
Who can join: Review the eligibility criteria below.
Location: Oregon Health & Science University — Portland, Oregon
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
- STELLA-FTD Control (BEHAVIORAL)
- STELLA-FTD Test (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Oregon Health & Science University — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (503) 568-9725
Email: chatterton@ohsu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Frontotemporal Dementia
- Neurofilament Surveillance Project (NSP) — San Francisco, California
- A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes — Ann Arbor, Michigan
- Music, Social Attention, and Dementia — San Francisco, California
- Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) — Maitland, Florida
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) — San Francisco, California
- Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia — Bethesda, Maryland
Explore by condition: All Frontotemporal Dementia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.